Most researchers seeking to take advantage of the role of the CXCR4 and CCR5 co-receptors on T cells in HIV infection are looking for small molecule antagonists that compete with virus for access to these receptors. But Richard Zheng of Queen Mary and Westfield College, London and Peter Eagles of King's College London are pursuing a different approach that actually halts the production of both co-receptors